[ad_1]
The Korányi National Institute of Pulmonology is also participating in the clinical trial of the nationally developed drug favipiravir, the institution’s acting director general said in a video sent to the hospital’s MTI on Saturday.
Krisztina Bogos emphasized: The study hopes to answer a number of questions, including how well the drug works in people with coronavirus infections, how safe it can be given, and at what stage of infection the treatment is used.Gábor Takács, the hospital’s chief pharmacist, called favipiravir the last promising option in the treatment of coronavirus. He said: the drug is not completely unknown, as it has already been used in Japan and China for other indications to treat influenza.
However, recent data suggests that it may also be effective in treating coronavirus. In any case, the results so far based on other clinical trials and data are extremely encouraging.– Gábor Takács emphasized, according to whom a clinical trial lasts months, is carried out according to a serious methodology and at the end a biostatistical evaluation is carried out. Because the study was recently launched, it takes several months for favipiravir to be truly effective. In addition to the coronavirus care, rehabilitation activities are also carried out in the hospital, said János Varga, head of the department. Patients who develop a lung transplant due to an advanced stage of chronic lung disease can be included in a rehabilitation program where they are cared for by internationally renowned professionals. The chief physician added that patients in need can receive an objective evaluation and then report to the Lung Transplant Tail Committee.
[ad_2]
